You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Baxter
Moodys
Medtronic
Harvard Business School

Last Updated: January 20, 2021

DrugPatentWatch Database Preview

Ribavirin - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for ribavirin and what is the scope of freedom to operate?

Ribavirin is the generic ingredient in five branded drugs marketed by Merck Sharp Dohme, Chartwell Rx, Aurobindo Pharma, Teva, Zydus Pharms Usa, Navinta Llc, Valeant Pharm Intl, Schering, Roche, Beximco Pharms Usa, Heritage Pharma, and Sandoz, and is included in sixteen NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Ribavirin has thirty-three patent family members in twenty-six countries.

There are fifteen drug master file entries for ribavirin. Nine suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for ribavirin

See drug prices for ribavirin

Recent Clinical Trials for ribavirin

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Witwatersrand, South AfricaPhase 2
SynaVirPhase 2
Rutgers, The State University of New JerseyPhase 2

See all ribavirin clinical trials

Generic filers with tentative approvals for RIBAVIRIN
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial40MG/MLSOLUTION; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ribavirin
Medical Subject Heading (MeSH) Categories for ribavirin
Paragraph IV (Patent) Challenges for RIBAVIRIN
Tradename Dosage Ingredient NDA Submissiondate
VIRAZOLE FOR SOLUTION;INHALATION ribavirin 018859 2014-05-22
REBETOL CAPSULE;ORAL ribavirin 020903

US Patents and Regulatory Information for ribavirin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering REBETOL ribavirin SOLUTION;ORAL 021546-001 Jul 29, 2003 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Zydus Pharms Usa RIBAVIRIN ribavirin TABLET;ORAL 077094-004 Apr 18, 2008 DISCN No No   Start Trial   Start Trial   Start Trial
Heritage Pharma RIBAVIRIN ribavirin TABLET;ORAL 077053-001 Dec 5, 2005 DISCN No No   Start Trial   Start Trial   Start Trial
Navinta Llc RIBAVIRIN ribavirin FOR SOLUTION;INHALATION 207366-001 Oct 6, 2016 AN RX No No   Start Trial   Start Trial   Start Trial
Chartwell Rx RIBASPHERE ribavirin CAPSULE;ORAL 076203-001 Apr 6, 2004 DISCN No No   Start Trial   Start Trial   Start Trial
Roche COPEGUS ribavirin TABLET;ORAL 021511-002 Jun 21, 2005 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ribavirin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme REBETOL ribavirin CAPSULE;ORAL 020903-001 Jun 3, 1998   Start Trial   Start Trial
Merck Sharp Dohme REBETOL ribavirin CAPSULE;ORAL 020903-001 Jun 3, 1998   Start Trial   Start Trial
Merck Sharp Dohme REBETOL ribavirin CAPSULE;ORAL 020903-002 Jul 25, 2001   Start Trial   Start Trial
Merck Sharp Dohme REBETOL ribavirin CAPSULE;ORAL 020903-001 Jun 3, 1998   Start Trial   Start Trial
Merck Sharp Dohme REBETOL ribavirin CAPSULE;ORAL 020903-002 Jul 25, 2001   Start Trial   Start Trial
Merck Sharp Dohme REBETOL ribavirin CAPSULE;ORAL 020903-002 Jul 25, 2001   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Colorcon
AstraZeneca
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.